Status:
UNKNOWN
Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay
Lead Sponsor:
West China Hospital
Conditions:
ST Elevation Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The OPTIMAL-REPERFUSION trial will help determine whether reduced-dose facilitated PCI strategy improves clinical outcomes in patients with STEMI and anticipated PPCI delay
Detailed Description
OPTIMAL-REPERFUSION is an investigator-initiated, prospective, multicenter, randomized, open-label, superiority trial with blinded evaluation of outcomes. A total of 632 STEMI patients presenting with...
Eligibility Criteria
Inclusion
- Aged 18 or over and less than 75 years old;
- Patents with STEMI with symptom onset persisted more than 30mim and within 6 h before randomization;
- ECG \>=2 mm ST-segment elevation in 2 contiguous precordial leads or \>=1 mm ST- segment elevation in 2 contiguous extremity leads, or new left bundle branch block;
- Patents with an expected time from FMC to PCI \>=120 min.
- Signed informed consent form prior to trial participation.
Exclusion
- Fibrinolysis contradictions: Definite hemorrhagic stroke history;ischemic stroke or cerebrovascular accident in nearly 6 months;
- Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \< 3 months);
- Active bleeding or known bleeding disorder/diathesis; Recent administration of any i.v. or s.c. anticoagulation within 12 hours including unfractionated heparin, enoxaparin and/or bivalirudin or current use of oral anticoagulation (warfarin or coumadin);
- Arterial aneurysm, arterial/venous malformation and aorta dissection; Uncontrolled hypertension, defined as a single blood pressure measurement \>=180/110 mm Hg (systolic BP \>=180 mm Hg and/or diastolic BP \>=110 mm Hg) prior to randomisation;
- Major surgery, biopsy of a parenchymal organ, noncompressible vascular puncture, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction);
- prolonged or traumatic cardiopulmonary resuscitation (\> 10 minutes) within the past 2 weeks; major surgery pending in the following 30 days. 2. Complex heart condition Evidence of cardiac rupture; Pre-existing heart failure and previous New York heart function classification III-IVCardiogenic shock (SBP \<90mmHg after fluid infusion or SBP\<100mmHg after vasoactive drugs);
- PCI within previous 1 month or previous bypass surgery;
- Myocardial infarction in the past year or previously known coronary artery disease not suitable for revascularization;
- Known acute pericarditis and/or subacute bacterial endocarditis;
- Hospitalization for cardiac reason within past 48 hours;
- Severe comorbidity: Other diseases with life expectancy \<=12 months;
- Any history of severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension or active hepatitis);
- neutropenia, thrombocytopenia;
- Severe COPD with hypoxemia;
- Not suitable for clinical trial: Inclusion in another clinical trial; Previous enrollment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days;
- Pregnant or lactating;
- Body weight \<40kg;
- Known hypersensitivity to any drug that may be used in the study;
- Inability to follow the protocol and comply with follow-up requirements or any other reason the investigator feels would place the patient at increased risk.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
632 Patients enrolled
Trial Details
Trial ID
NCT04752345
Start Date
March 1 2021
End Date
September 1 2023
Last Update
February 12 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.